Global CRISPR/Cas9 Market Size, Status and Forecast 2019-2025

2 Global CRISPR/Cas9 Quarterly Market Size Analysis

• 2.1 CRISPR/Cas9 Business Impact Assessment - COVID-19
  • 2.1.1 Global CRISPR/Cas9 Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global CRISPR/Cas9 Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global CRISPR/Cas9 Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, CRISPR/Cas9 Headquarters and Area Served
• 3.3 Date of Key Players Enter into CRISPR/Cas9 Market
• 3.4 Key Players CRISPR/Cas9 Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on CRISPR/Cas9 Segments, By Type

• 4.1 Introduction
  • 1.4.1 Genome Editing
  • 1.4.2 Genetic engineering
  • 1.4.3 gRNA Database/Gene Librar
  • 1.4.4 CRISPR Plasmid
  • 1.4.5 Human Stem Cells
  • 1.4.6 Genetically Modified Organisms/Crops
  • 1.4.7 Cell Line Engineering
• 4.2 By Type, Global CRISPR/Cas9 Market Size, 2019-2021

5 Impact of Covid-19 on CRISPR/Cas9 Segments, By Application

• 5.1 Overview
  • 5.5.1 Biotechnology Companies
  • 5.5.2 Pharmaceutical Companies
  • 5.5.3 Academic Institutes
  • 5.5.4 Research and Development Institutes
• 5.2 By Application, Global CRISPR/Cas9 Market Size, 2019-2021
  • 5.2.1 By Application, Global CRISPR/Cas9 Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Caribou Biosciences
  • 7.1.1 Caribou Biosciences Business Overview
  • 7.1.2 Caribou Biosciences CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.1.3 Caribou Biosciences CRISPR/Cas9 Product Introduction
  • 7.1.4 Caribou Biosciences Response to COVID-19 and Related Developments
• 7.2 Integrated DNA Technologies (IDT)
  • 7.2.1 Integrated DNA Technologies (IDT) Business Overview
  • 7.2.2 Integrated DNA Technologies (IDT) CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.2.3 Integrated DNA Technologies (IDT) CRISPR/Cas9 Product Introduction
  • 7.2.4 Integrated DNA Technologies (IDT) Response to COVID-19 and Related Developments
• 7.3 CRISPR Therapeutics
  • 7.3.1 CRISPR Therapeutics Business Overview
  • 7.3.2 CRISPR Therapeutics CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.3.3 CRISPR Therapeutics CRISPR/Cas9 Product Introduction
  • 7.3.4 CRISPR Therapeutics Response to COVID-19 and Related Developments
• 7.4 Merck
  • 7.4.1 Merck Business Overview
  • 7.4.2 Merck CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.4.3 Merck CRISPR/Cas9 Product Introduction
  • 7.4.4 Merck Response to COVID-19 and Related Developments
• 7.5 Mirus Bio
  • 7.5.1 Mirus Bio Business Overview
  • 7.5.2 Mirus Bio CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.5.3 Mirus Bio CRISPR/Cas9 Product Introduction
  • 7.5.4 Mirus Bio Response to COVID-19 and Related Developments
• 7.6 Editas Medicine
  • 7.6.1 Editas Medicine Business Overview
  • 7.6.2 Editas Medicine CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.6.3 Editas Medicine CRISPR/Cas9 Product Introduction
  • 7.6.4 Editas Medicine Response to COVID-19 and Related Developments
• 7.7 Takara Bio
  • 7.7.1 Takara Bio Business Overview
  • 7.7.2 Takara Bio CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.7.3 Takara Bio CRISPR/Cas9 Product Introduction
  • 7.7.4 Takara Bio Response to COVID-19 and Related Developments
• 7.8 Thermo Fisher Scientific
  • 7.8.1 Thermo Fisher Scientific Business Overview
  • 7.8.2 Thermo Fisher Scientific CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.8.3 Thermo Fisher Scientific CRISPR/Cas9 Product Introduction
  • 7.8.4 Thermo Fisher Scientific Response to COVID-19 and Related Developments
• 7.9 Horizon Discovery Group
  • 7.9.1 Horizon Discovery Group Business Overview
  • 7.9.2 Horizon Discovery Group CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.9.3 Horizon Discovery Group CRISPR/Cas9 Product Introduction
  • 7.9.4 Horizon Discovery Group Response to COVID-19 and Related Developments
• 7.10 Intellia Therapeutics
  • 7.10.1 Intellia Therapeutics Business Overview
  • 7.10.2 Intellia Therapeutics CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.10.3 Intellia Therapeutics CRISPR/Cas9 Product Introduction
  • 7.10.4 Intellia Therapeutics Response to COVID-19 and Related Developments
• 7.11 Agilent Technologies
  • 7.11.1 Agilent Technologies Business Overview
  • 7.11.2 Agilent Technologies CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.11.3 Agilent Technologies CRISPR/Cas9 Product Introduction
  • 7.11.4 Agilent Technologies Response to COVID-19 and Related Developments
• 7.12 Cellecta
  • 7.12.1 Cellecta Business Overview
  • 7.12.2 Cellecta CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.12.3 Cellecta CRISPR/Cas9 Product Introduction
  • 7.12.4 Cellecta Response to COVID-19 and Related Developments
• 7.13 GenScript
  • 7.13.1 GenScript Business Overview
  • 7.13.2 GenScript CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.13.3 GenScript CRISPR/Cas9 Product Introduction
  • 7.13.4 GenScript Response to COVID-19 and Related Developments
• 7.14 GeneCopoeia
  • 7.14.1 GeneCopoeia Business Overview
  • 7.14.2 GeneCopoeia CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.14.3 GeneCopoeia CRISPR/Cas9 Product Introduction
  • 7.14.4 GeneCopoeia Response to COVID-19 and Related Developments
• 7.15 Synthego
  • 7.15.1 Synthego Business Overview
  • 7.15.2 Synthego CRISPR/Cas9 Quarterly Revenue, 2020
  • 7.15.3 Synthego CRISPR/Cas9 Product Introduction
  • 7.15.4 Synthego Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US